HK1162150A1 - 減少非腦組織中的β-澱粉樣蛋白的量 - Google Patents
減少非腦組織中的β-澱粉樣蛋白的量Info
- Publication number
- HK1162150A1 HK1162150A1 HK12102739.8A HK12102739A HK1162150A1 HK 1162150 A1 HK1162150 A1 HK 1162150A1 HK 12102739 A HK12102739 A HK 12102739A HK 1162150 A1 HK1162150 A1 HK 1162150A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- reduction
- brain tissue
- amyloid beta
- beta load
- non brain
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 210000005013 brain tissue Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11445908P | 2008-11-13 | 2008-11-13 | |
| US23092609P | 2009-08-03 | 2009-08-03 | |
| PCT/US2009/064430 WO2010057020A2 (en) | 2008-11-13 | 2009-11-13 | Modification of amyloid-beta load in non-brain tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1162150A1 true HK1162150A1 (zh) | 2012-08-24 |
Family
ID=42165803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12102739.8A HK1162150A1 (zh) | 2008-11-13 | 2012-03-19 | 減少非腦組織中的β-澱粉樣蛋白的量 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100120787A1 (zh) |
| EP (1) | EP2365804B1 (zh) |
| JP (2) | JP2012508770A (zh) |
| CN (1) | CN102271669A (zh) |
| AU (1) | AU2009313851A1 (zh) |
| CA (1) | CA2742771A1 (zh) |
| DK (1) | DK2365804T3 (zh) |
| ES (1) | ES2543987T3 (zh) |
| HK (1) | HK1162150A1 (zh) |
| HU (1) | HUE027027T2 (zh) |
| MX (1) | MX2011004891A (zh) |
| PL (1) | PL2365804T3 (zh) |
| PT (1) | PT2365804E (zh) |
| WO (1) | WO2010057020A2 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029481B1 (ru) * | 2007-01-05 | 2018-04-30 | Юнивэсэти Оф Цюрих | Способ получения человеческого рекомбинантного антитела, специфично связывающего вариант эндогенного белка, формирующий аномальные патологические белковые структуры путем агрегации, олигомеризации или образования фибрилл |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| JP5559043B2 (ja) * | 2007-06-07 | 2014-07-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 新規ヘテロ環化合物およびその使用 |
| EP2166858A4 (en) * | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | NEW HETEROCYCLIC COMPOUNDS AND ITS USE |
| EP2949666B1 (en) | 2008-12-19 | 2018-12-19 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| WO2012080703A1 (en) * | 2010-12-15 | 2012-06-21 | Cipla Limited | Pharmaceutical composition comprising imatinib |
| AU2012272790B2 (en) | 2011-06-23 | 2016-10-06 | Biogen International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
| EP2776035B1 (en) * | 2011-11-01 | 2016-08-10 | Modgene, Llc | Compositions and methods for reduction of amyloid-beta load |
| EP3584327A1 (en) | 2012-01-27 | 2019-12-25 | The Board of Trustees of the Leland Stanford Junior University | Methods for profiling and quantitating cell-free rna |
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN105018484B (zh) * | 2015-07-31 | 2017-10-13 | 北京泱深生物信息技术有限公司 | Crtap基因及其表达产物作为阿尔茨海默病的诊治靶标 |
| CN105651840B (zh) * | 2016-04-01 | 2017-12-26 | 商丘师范学院 | 一种检测β‑淀粉样蛋白寡聚体的类免疫电化学传感器及其制备方法 |
| FI3672631T3 (fi) | 2017-08-22 | 2023-06-29 | Biogen Ma Inc | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3249793A (en) * | 1991-12-24 | 1993-07-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating beta -amyloid |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| PT730643E (pt) * | 1993-10-27 | 2001-06-29 | Lilly Co Eli | Animais transgenicos portadores do alelo de app com mutacao sueca |
| AU2001257022B2 (en) * | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| US20080032942A1 (en) * | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| ES2215494T5 (es) * | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
| AU2003206397B2 (en) * | 2002-01-04 | 2008-07-17 | The Rockefeller University | Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| AT413944B (de) * | 2003-05-27 | 2006-07-15 | Binder Eva Dkfm | Verwendung von oxicam-verbindungen |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| US20070134724A1 (en) * | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
| WO2007103683A2 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
| WO2007139120A1 (ja) * | 2006-05-30 | 2007-12-06 | Osaka University | アミロイドβクリアランス促進剤 |
| JP5675344B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのニトロビニルジアミン誘導体 |
-
2009
- 2009-11-13 WO PCT/US2009/064430 patent/WO2010057020A2/en active Application Filing
- 2009-11-13 ES ES09761084.4T patent/ES2543987T3/es active Active
- 2009-11-13 EP EP09761084.4A patent/EP2365804B1/en not_active Not-in-force
- 2009-11-13 PL PL09761084T patent/PL2365804T3/pl unknown
- 2009-11-13 CN CN2009801543479A patent/CN102271669A/zh active Pending
- 2009-11-13 DK DK09761084.4T patent/DK2365804T3/en active
- 2009-11-13 AU AU2009313851A patent/AU2009313851A1/en not_active Abandoned
- 2009-11-13 PT PT97610844T patent/PT2365804E/pt unknown
- 2009-11-13 JP JP2011536527A patent/JP2012508770A/ja active Pending
- 2009-11-13 MX MX2011004891A patent/MX2011004891A/es unknown
- 2009-11-13 CA CA2742771A patent/CA2742771A1/en not_active Abandoned
- 2009-11-13 HU HUE09761084A patent/HUE027027T2/en unknown
- 2009-11-13 US US12/618,656 patent/US20100120787A1/en not_active Abandoned
-
2012
- 2012-03-19 HK HK12102739.8A patent/HK1162150A1/zh not_active IP Right Cessation
-
2015
- 2015-05-13 JP JP2015098095A patent/JP2015172061A/ja active Pending
- 2015-11-04 US US14/932,403 patent/US20160287587A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009313851A1 (en) | 2010-05-20 |
| WO2010057020A3 (en) | 2010-11-25 |
| CN102271669A (zh) | 2011-12-07 |
| CA2742771A1 (en) | 2010-05-20 |
| EP2365804B1 (en) | 2015-05-06 |
| US20160287587A1 (en) | 2016-10-06 |
| JP2012508770A (ja) | 2012-04-12 |
| PT2365804E (pt) | 2015-09-16 |
| WO2010057020A2 (en) | 2010-05-20 |
| HUE027027T2 (en) | 2016-08-29 |
| PL2365804T3 (pl) | 2015-10-30 |
| JP2015172061A (ja) | 2015-10-01 |
| US20100120787A1 (en) | 2010-05-13 |
| DK2365804T3 (en) | 2015-07-27 |
| ES2543987T3 (es) | 2015-08-26 |
| MX2011004891A (es) | 2011-10-06 |
| EP2365804A2 (en) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1162150A1 (zh) | 減少非腦組織中的β-澱粉樣蛋白的量 | |
| HRP20181803T1 (hr) | Serumski amiloidni p derivati i njihova priprava i uporaba | |
| EP2244712A4 (en) | IN VIVO EXAMINATIONS OF CRYSTALLINE FORMS OF MELOXICAM | |
| IL208458A0 (en) | Compositions and methods for skin care | |
| ZA201100974B (en) | Treatment of autoimmune and inflammatory disease | |
| IL216128A (en) | Antibodies to ngf with increased in vivo stability | |
| EP2338457A4 (en) | MEDICAL BED | |
| EP2240017A4 (en) | CEONIC BODIES AND ESTERS OF CERAMIC BODIES SUITABLE AS BLOOD HYPOLIPEMENTS | |
| PL2647337T3 (pl) | Urządzenie wywołujące bodźce skóry | |
| HK1184053A1 (zh) | 用於皮膚增强的蘆薈製劑 | |
| HK1156867A1 (en) | External preparation for skin | |
| EP2411006A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS | |
| GB0908193D0 (en) | Treatment of disease state | |
| EP2408740A4 (en) | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND PAIN | |
| EP2405928A4 (en) | Methods of treatment and diagnosis for hypersensitivity disorders | |
| IL214133A0 (en) | Skin treatment | |
| GB0918392D0 (en) | Diagnostic and therapeutic methods | |
| HK1157228A1 (en) | Compositions and methods of treating amyloid disease | |
| EP2198040A4 (en) | IN VIVO FIGURE OF MYELIN | |
| EP2488198A4 (en) | TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS | |
| GB0917612D0 (en) | In vivo imaging agents | |
| ZA201101821B (en) | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin deases | |
| GB0908101D0 (en) | Treatment of stress | |
| ZA201005770B (en) | The treatment of damaged skin | |
| GB0901175D0 (en) | The treatment of skin aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20201109 |